Baillie Gifford & Co’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Baillie Gifford & Co’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-360,650	Closed	-$2.17M	–	203
2015 Q4	$2.17M	Hold	360,650	–	–	﹤0.01%	172
2015 Q3	$2.82M	Hold	360,650	–	–	0.01%	179
2015 Q2	$2.21M	Hold	360,650	–	–	﹤0.01%	181
2015 Q1	$2.9M	Hold	360,650	–	–	0.01%	180
2014 Q4	$1.82M	Hold	360,650	–	–	﹤0.01%	184
2014 Q3	$1.87M	Hold	360,650	–	–	﹤0.01%	188
2014 Q2	$2.8M	Hold	360,650	–	–	0.01%	184
2014 Q1	$2.52M	Buy	360,650 +256,650	+247%	+$2M	0.01%	184
2013 Q4	$623K	Buy	104,000 +56,145	+117%	+$367K	﹤0.01%	190
2013 Q3	$373K	Buy	47,855 +25,000	+109%	+$116K	﹤0.01%	182
2013 Q2	$87K	Buy	+22,855	New	+$93.7K	﹤0.01%	178

Other funds holding GNMX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baillie Gifford & Co's GNMX Position: Q1 2016 in Review

Baillie Gifford & Co sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2016, closing a stake of 360,650 shares — an estimated $2.17M sold.

Baillie Gifford & Co first reported a position in GNMX in Q2 2013 and held it in 11 quarters. The position peaked at $2.9M in Q1 2015. 56 funds tracked by Wall St. Rank hold GNMX as of Q1 2016.

Baillie Gifford & Co reported no remaining Aevi Genomic Medicine Inc position as of Q1 2016 after selling out during the quarter.
Baillie Gifford & Co sold 360,650 Aevi Genomic Medicine Inc shares in Q1 2016, an estimated $2.17M.
Baillie Gifford & Co first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 11 quarters.
Baillie Gifford & Co's Aevi Genomic Medicine Inc position peaked at $2.9M in Q1 2015.
56 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2016.

Based on Baillie Gifford & Co's 13F filing for Q1 2016, filed 5 May 2016.